Contract analysis
Clause-by-clause risk read on any document of the firm. Pick a contract, or open any document from a matter.
Contract analysis / series-b-preferred-consent.docx
series-b-preferred-consent.docx
High · 0
Medium · 1
Standard · 0
WRITTEN CONSENT OF THE HOLDERS OF A MAJORITY OF THE OUTSTANDING SHARES OF SERIES B PREFERR
Medium
⚑ Notice / time limit to track
WRITTEN CONSENT OF THE HOLDERS OF A MAJORITY OF THE OUTSTANDING SHARES OF SERIES B PREFERRED STOCK OF GENOME DX THERAPEUTICS INC. ACTION BY WRITTEN CONSENT IN LIEU OF A MEETING Dated: September 10, 2025 The undersigned is a holder of shares of Series B Preferred Stock, par value $0.0001 per share (the "Series B Preferred Stock"), of Genome Dx Therapeutics Inc., a corporation organized and existing under the laws of t